Differential diagnostic capabilities of calculating the level of neutrophil extracellular traps in the venous blood of pregnant women: a comparative prospective study

N. B. Kuzina1, E. N. Plakhotina2, A. N. Kuzovlev2, T. N. Belousova2, E. V. Bryantsev2, D. V. Kasina2

1 Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitation, Moscow, Russia
2 Vidnovsky perinatal center, Vidnoye, Russia
3 Moscow Regional Research and Clinical Institute, Moscow, Russia

Abstract

Introduction. Severe preeclampsia in early stages can be detected by isolated thrombocytopenia, which makes it difficult to diagnose it in time and carry out the necessary therapeutic measures. As a rule, the diagnosis of severe preeclampsia can be declared with a detailed clinical and laboratory researches, and it increases the risks for the mother and the embryo. However, if there are no clinical symptoms of preeclampsia except of thrombocytopenia, there is a problem of differential diagnosis between thrombocytopenia, which has the same symptoms as preeclampsia and gestational thrombocytopenia, which is a physiological peculiarity and does not require any medical interventions and restrictions. Nowadays there are no screening methods for differential diagnosis of these conditions. Objectives. To estimate the possibilities of determining the level of neutrophil extracellular traps (NETs) during the differential diagnosis of preeclampsia and gestational thrombocytopenia. Materials and methods. The comparative analysis of the level of NETs was carried out in three groups of pregnant women. Group 1 included patients with severe preeclampsia (n = 45), group 2-patients with gestational thrombocytopenia (n = 44) and group 3 consisted of healthy pregnant women (n = 44). Results. The research revealed significant increase in the level of NETs in the group of patients with preeclampsia (15.26 %) compared with the groups of healthy patients (7.65 %, p = 0.001) and patients with gestational thrombocytopenia (7.04 %, p = 0.002). There were no significant differences in the level of NETs between the groups of healthy patients and controls.

Referat

Актуальность. Тяжелая пreeклампсия на ранних стадиях заболевания может проявляться исключительно изолированной тромбоцитопенией, что затрудняет ее своевременную диагностику и проведение необходимых лечебных мероприятий. Как правило, диагноз тяжелой пreeклампсии выставляется при развернутой клиническо-лабораторной картине этого осложнения, что увеличивает риски для матери и плода. Однако, если клинических проявлений пreeклампсии кроме тромбоцитопении нет, существует проблема дифференциально-диагностической диагностики между тромбоцитопенией, являющейся проявлением пreeклампсии, и гестационной тромбоцитопенией, которая является физиологической и не требует каких-либо вмешательств и ограничений.

В настоящее время не существует скрининговых методов дифференциальной диагностики этих состояний. Цель исследования. Оценить возможности метода определения уровня нейтрофильных внеклеточных ловушек (НВЛ) при проведении дифференциального диагноза между пreeклампсией и гестационной тромбоцитопенией. Материалы и методы. Межгрупповой сравнительный анализ уровня НВЛ был проведен в трех группах беременных.
patients with gestational thrombocytopenia. Conclusions. A significant increase of the level of NETs among the patients with severe preeclampsia allows us to consider the method of calculating the level of NETs among patients with thrombocytopenia which can be detected after the 20th week of pregnancy, if there are no other laboratory and clinical signs of preeclampsia as a screening method for early diagnosis of this complication.

**Keywords:** pregnancy, pre-eclampsia, thrombocytopenia, neutrophil extracellular traps.

For correspondence: Artem N. Kuzovlev, MD, PhD, head of the V. Negovsky research Institute of General Reanimatology and Resuscitation, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia; e-mail: artem_kuzovlev@mail.ru


Received: 04.10.2021
Accepted: 30.11.2021
Published online: 19.01.2022

В группу № 1 вошли пациентки с тяжелой преэклампсией (n = 45), в группу № 2 — пациентки с гестационной тромбоцитопенией (n = 44) и группу № 3 (контрольную) составили беременные без тромбоцитопении и преэклампсии (n = 44). Результаты. Проведенное исследование выявило значимое увеличение уровня НВЛ в группе пациенток с преэклампсий (среднее 15,26 %) по сравнению с группами беременных без тромбоцитопений (среднее 7,65 %, p = 0,001) и пациенток с гестационной тромбоцитопенией (среднее 7,04 %, р = 0,002). Значимых различий в уровне НВЛ между группами беременных без тромбоцитопений и пациенток с гестационной тромбоцитопенией не выявлено. Заключение. Значимое увеличение уровня НВЛ у пациенток с тяжелой преэклампсией позволяет рассматривать метод подсчета уровня НВЛ у пациенток с тромбоцитопений, выявленной после 20-й недели беременности, при отсутствии других лабораторных и клинических признаков преэклампсии как скрининговый для ранней диагностики этого осложнения.

**Ключевые слова:** беременность, преэклампсия, тромбоцитопения, нейтрофильные внеклеточные ловушки

Для корреспонденции: Кузовлев Артем Николаевич — д-р мед. наук, заместитель директора — руководитель НИИ общей реаниматологии им. В.А. Неговского ФНКЦ РР, заведующий кафедрой анестезиологии-реаниматологии ИВД-ПО ФНКЦ РР, ФГБНУ «Федеральный научно-клинический центр реаниматологии и реабилитологии», Москва; e-mail: artem_kuzovlev@mail.ru

Для цитирования: Кузнёва Н.Б., Плахотина Е.Н., Кузовлев А.Н., Белоусова Т.Н., Брянцев Е.В., Касина Д.В. Дифференциально-диагностические возможности подсчета уровня нейтрофильных внеклеточных ловушек в венозной крови беременных: сравнительное проспективное исследование. Вестник интенсивной терапии им. А.И. Салтанова. 2021;4:79–87. DOI: 10.21320/1818-474X-2021-4-79-87

Поступила: 04.10.2021
Принята к печати: 30.11.2021
Дата онлайн-публикации: 19.01.2022

DOI: 10.21320/1818-474X-2021-4-79-87
Background

In 2004, A. Zychlinsky et al. described the phenomenon of neutrophils neutralizing pathogenic microorganisms through extracellular structures called “neutrophil extracellular traps” (NETs). Since the neutrophil dies during the formation of the traps, the mechanism of their production was named NETosis, similar to apoptosis and necrosis [1].

According to a literature report, percentage of NETs in healthy donors was 5.7±2.5% (Min-Max: 1.8% - 11.9%) [2].

Many studies show that the NET formation plays an important role in the pathogenesis of systemic lupus erythematosus [3], preeclampsia [4,5], sepsis [6,7,8], cystic fibrosis [9], immunocomplex diseases [10], inflammatory bowel disease [11], atherosclerosis [12], antiphospholipid syndrome [13,14].

In preeclampsia, reduced placental perfusion is associated, among others, with an increased release of inflammatory membrane microparticles of syncytiotrophoblast microvilli and cytokines in response to primary hypoxia caused by initially impaired trophoblast invasion. Increased blood levels of syncytiotrophoblast microvilli have been found in patients with preeclampsia. Studies have shown that syncytiotrophoblast microvilli destroy endothelium and inhibit endothelial cell proliferation in culture as well as endothelium-dependent relaxation of small arteries in vitro [15,16,17,18]. Inadequate placental perfusion in preeclampsia has been suggested to produce reactive oxygen species, which are inducers of NETosis. As a consequence, a vicious circle develops where initial hypoxia caused by malformation of spiral arteries and related oxidative stress induces neutrophils to form traps, which aggravate abnormal placental blood flow by increasing hypoxia and oxidative stress [5,19,20,21,22,23].

Severe pre-eclampsia is characterized by rapid progression of clinical manifestations and such complications as intrauterine fetal growth delay (8-20%) [24], premature placental detachment [25], preeclampsia (8%) [26], HELLP syndrome (4-12%) [27]. This complication ranks fourth among the causes of maternal mortality [24]. Preeclampsia results in over 70,000 maternal and 500,000 intrauterine/neonatal deaths annually worldwide [28]. When severe preeclampsia manifests as isolated thrombocytopenia, timely diagnosis and ruling out other types of thrombocytopenia, especially very common gestational one, are necessary.

Currently, the diagnosis of severe preeclampsia is made based on typical clinical and laboratory presentations. However, an atypical manifestation of the disease can reduce the awareness of preeclampsia, prompting the physician to diagnose gestational thrombocytopenia. This approach can lead to inappropriate patient management and result in major complications of preeclampsia. It is difficult to confirm or rule out pre-eclampsia in its early stages without a typical clinical presentation, even if the clinician is alert. Diagnostic markers of early pre-eclampsia, such as the sflt-1/plgf ratio, are not readily available in routine clinical practice [29]. Overdiagnosis of this complication entails unwarranted polypharmacy and interventions, including premature delivery, which are not necessary in gestational thrombocytopenia. On the other hand, there are currently no strict diagnostic criteria for gestational thrombocytopenia and this diagnosis is usually made after ruling out the other possible conditions. Gestational thrombocytopenia is physiological in nature and usually does not associate with coagulation disorders nor requires any intervention and subsides after delivery [30,31].

Thus, there is currently no available screening method for differential diagnosis of early severe preeclampsia and other conditions associated with thrombocytopenia, including gestational one.

The objective of the study was to evaluate the value of NETs assessment in the differential diagnosis between preeclampsia and gestational thrombocytopenia.

Materials and methods

This comparative prospective clinical study of the venous blood levels of NETs in patients with severe preeclampsia, gestational thrombocytopenia, and healthy pregnant women was performed at the Vidnoye Perinatal Center (Fig. 1). The patients were assigned to 3 study groups. The sample size was estimated using the relevant determination tables [32].

Patients were recruited without randomization until the predefined number was reached. Patients were allocated into groups after the diagnoses of severe preeclampsia and gestational thrombocytopenia had been confirmed or ruled out. Group 1 included 45 patients diagnosed with severe pre-eclampsia using the following criteria: diastolic BP greater than or equal to 110 mm Hg, systolic BP greater than or equal to 160 mm Hg, daily proteinuria greater than 5 g/L, and/or one or more additional criteria for severe preeclampsia (HELLP syndrome, persistent headaches, vomiting, other cerebral or visual disturbances, renal dysfunction, acute lung injury, pulmonary edema, optic edema, liver dysfunction, epigastric/right upper quadrant pain, thrombocytopenia and/or its progression, sudden-onset/progressive edema, evidence of fetal distress) [33].

Group 2 included 44 patients diagnosed with gestational thrombocytopenia using the following criteria: platelet count reduction during current pregnancy below 150,000.

In order to quantify the level of NETs, the venous blood was collected from patients in the II-III trimesters of pregnancy in RusTech and PUTH general blood test tubes with EDTA. Later, a blood smear with a dense monolayer of cells was made within 1.5 hours of the sampling and examined according to the technique described in
DIAGNOSTIC APPROACHES AND FORECASTING IN THE INTENSIVE CARE

Enrollment of patients diagnosed with severe preeclampsia, gestational thrombocytopenia, and healthy pregnant women (n=168)

Exclusion from the study according to exclusion criteria (n=11):
- history of neoplastic disease or diagnosis of cancer at the time of the study (n=1)
- history of syphilis or its diagnosis at the time of the study (n=1)
- hereditary thrombophilia (n=4)
- active chronic infectious diseases (n=4)
- antiphospholipid syndrome (n=1)

Allocation to groups according to inclusion criteria (n=157)

Group 1 (patients with severe preeclampsia) (n=52)
Group 2 (patients with gestational thrombocytopenia) (n=55)
Group 3 (healthy pregnant women) (n=50)

Measurement of NETs in the venous blood of participants

Included in the analysis (n=45)
- Rh-negative blood (n=4)
- Multiple gestation pregnancy (n=2)
- Gestational diabetes mellitus requiring insulin therapy (n=1)

Excluded from the analysis (n=7)*
- Rh-negative blood (n=4)
- Multiple gestation pregnancy (n=2)
- Gestational diabetes mellitus requiring insulin therapy (n=1)

Included in the analysis (n=44)
- Rh-negative blood (n=4)
- Multiple gestation pregnancy (n=5)
- Gestational diabetes mellitus requiring insulin therapy (n=2)

Excluded from the analysis (n=6)*
- Rh-negative blood (n=5)
- Multiple gestation pregnancy (n=1)
- Gestational diabetes mellitus requiring insulin therapy (n=0)

* Analysis of the data obtained in this category of patients revealed a significant increase in the level of NETs, which requires further study.

Figure 1. Flow chart of comparative prospective clinical study on the measurement and comparison of the NET level in the venous blood of patients with severe preeclampsia, gestational thrombocytopenia and healthy pregnant women.

Russian patent No. 2121297 “Method for determining the percentage of NETotic phagocytes” using a smear making device (Medtekhnopark LLC). The method consists in sliding the edge of the top slide on the working surface of the bottom slide to produce a uniform blood smear one layer of red blood cells thick with the red blood cell density of 4-15 thousand per mm. For this purpose, 2 µl of sampled blood was used, the smears obtained were stained using Giemsa stain. Quantification of NETs generated by NETotic blood phagocytes was performed using the MECOS-C2 automated microscopy complex (MECOS CJSC) and synthetic immersion oil (Minimed LLC).

In all prepared smears, the native phagocyte count ($C_{nat}$) and destroyed altered phagocyte count ($C_{destr}$), considered as NET marker, were calculated. The level of NETs was calculated according to the following formula:

$$\text{NETs level} = \frac{C_{destr}}{C_{nat} - C_{destr}} \%$$

All analyzed data were checked for normality of distribution. In normal distribution, parametric criteria were used for description such as mean and standard deviation. Analysis of variance and Student's t-criterion were used for comparative analysis of the studied groups in this case. If data distribution was non-normal, the results were presented as median (M) and 1st and 3rd quartiles (Q1-Q3) and Kruskal-Wallace and Mann-Whitney U-tests were used for comparative analysis. Pearson's $\chi^2$ test was used to analyze the qualitative data. Differences were considered significant at P value <0.05. Statistical analysis was done using Statistica 10 software (StatSoft Inc., USA).

This study was approved by the ethical committee of the V.A. Negovsky Research Institute of General Reanimatology, Moscow (protocol no. 2/20/3, dated June 10, 2020).

Results

When analyzing the age and body measurements (Table 1), no differences were found between the studied groups. The gestational age of studied patients (Table 1) was significantly lower in group 1 than in group 2 ($p=0.000001$, Mann-Whitney U-criterion) and in group 3 ($p=0.0002$, Mann-Whitney U-criterion). This difference can be explained by the frequent need for premature delivery in patients with severe preeclampsia. No differences in gestational age were found in groups 2 and 3 (Mann-Whitney
Differential diagnostic capabilities of calculating the level of neutrophil extracellular traps

U-criterion p>0.05). The higher incidence of preeclampsia in first-pregnant women [35,36,37] explains the prevalence of first-pregnant patients in group 1 compared with group 2 (p=0.006, Mann-Whitney U-criterion) and Group 3 (p=0.006, Mann-Whitney U-criterion) (Table 1). There were no significant differences between groups 2 and 3 (Mann-Whitney U-criterion, p>0.05).

Table 1. Characteristics of the studied groups

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group 1</th>
<th>Group 2</th>
<th>Group 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>31 (23-37)</td>
<td>30 (27-31.5)</td>
<td>31 (25-35)</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>30.2 (25.4-35.9)</td>
<td>27.9 (25.6-29.5)</td>
<td>28.3 (26.3-29.6)</td>
</tr>
<tr>
<td>Gestation period, weeks</td>
<td>36.3 (30-38)*</td>
<td>39 (37.5-39.2)</td>
<td>39 (38-39.6)</td>
</tr>
<tr>
<td>Parity</td>
<td>1 (1-2)*</td>
<td>2 (1-2.25)</td>
<td>2 (1-2.75)</td>
</tr>
</tbody>
</table>

Note. The data are given as Me (Q1-Q3).

Most common comorbidities in the study participants included genitourinary and endocrine disorders (including overweight and obesity), and mild anemia. Prevalence of endocrine diseases, overweight and obesity in group 1, which accounted for 40.3% of the total comorbidity, is consistent with the published data on increased risk of preeclampsia in patients with these conditions [35,36,37] (Table 2).

The differences in the number of patients in the groups and comorbidities were due to several concomitant diseases in some patients.

Thus, the intergroup differences in specific comorbidities and their frequencies are due to high incidence of endocrine diseases and overweight/obesity. According to current concepts, overweight and obesity, while being risk factors for preeclampsia, do not play a significant role in the pathogenesis of this pregnancy complication and could not affect the results of this study [35,36,37].

The levels of NETs in the study groups are shown in Table 3.

Table 3. NET levels in the study groups

<table>
<thead>
<tr>
<th>Mean</th>
<th>Minimum</th>
<th>Maximum</th>
<th>Standard deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1 (n=45), %</td>
<td>15.3*</td>
<td>5.8</td>
<td>28.7</td>
</tr>
<tr>
<td>Group 2 (n=44), %</td>
<td>7.2</td>
<td>0.9</td>
<td>13.4</td>
</tr>
<tr>
<td>Group 3 (n=44), %</td>
<td>7.7</td>
<td>1</td>
<td>13.7</td>
</tr>
</tbody>
</table>

* - p<0.05 (Student’s t-test) vs groups 2 and 3.

The analysis of variance revealed significant intergroup differences in NETs levels (p=0.003). In a pairwise comparison of groups using Student’s t-criterion, group 1 (patients with preeclampsia) had significantly higher NETs than group 2 (gestational thrombocytopenia) (p=0.002). Comparison of the preeclampsia group values with those of healthy pregnant women (group 3) also revealed significant differences (p=0.001). The levels of NETs did not differ between groups 2 and 3 (p>0.05, Student’s t-test).

Discussion

Due to lack of generally accepted reference values of the NETs level in the venous blood of pregnant women, the mean value of group 3 NETosis percentage was taken as reference and was 4.45-10.85% (7.65±3.2%, Min-Max: 1% to 13.7%).

Table 2. Comorbidities and their frequencies in the studied groups

<table>
<thead>
<tr>
<th>Comorbidity</th>
<th>Group 1 n=45</th>
<th>Group 2 n=44</th>
<th>Group 3 n=44</th>
<th>P-value (χ²-test)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild anemia</td>
<td>6 (9%)</td>
<td>8 (25.8%)</td>
<td>6 (15%)</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Large varicose veins</td>
<td>8 (11.9 %)</td>
<td>3 (9.7%)</td>
<td>3 (7.5%)</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal diseases</td>
<td>3 (4.5%)</td>
<td>7 (22.5%)</td>
<td>3 (7.5%)</td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal diseases</td>
<td>0</td>
<td>0</td>
<td>2(5%)</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular diseases</td>
<td>6 (9%)</td>
<td>1 (3.3%)</td>
<td>6 (15%)</td>
<td></td>
</tr>
<tr>
<td>Respiratory diseases</td>
<td>2 (2.9%)</td>
<td>0</td>
<td>2(5%)</td>
<td></td>
</tr>
<tr>
<td>Endocrine diseases, overweight and obesity</td>
<td>27(40.3%)</td>
<td>7 (22.5%)</td>
<td>5 (12.5%)</td>
<td></td>
</tr>
<tr>
<td>Neurological diseases</td>
<td>3 (4.5%)</td>
<td>0</td>
<td>2 (5%)</td>
<td></td>
</tr>
<tr>
<td>Genitourinary diseases</td>
<td>12 (17.9%)</td>
<td>5 (16.2%)</td>
<td>11 (27.5%)</td>
<td></td>
</tr>
</tbody>
</table>
The increase in NETs in preeclampsia found in this study is in accordance with previously published data. Similar results were obtained by A.K. Gupta et al. who showed that both microvilli of syncytiotrophoblast and soluble placental factors in vitro activate neutrophils to generate NETs. They also revealed that the traps were capable of ensnaring not only large objects, such as bacteria (>2 μm), but also very small (<200 nm) particles, such as microvilli of syncytiotrophoblast. In preeclampsia, the number of NETs in the placenta was significantly higher than in the placenta of healthy pregnant women [20].

Epithelial and endothelial dysfunction in preeclampsia may also be associated with increased levels of NETs, as shown by M. Saffarzadeh et al. who demonstrated a direct toxic effect of NET components on endothelium [38].

The procoagulant effect of traps, proven by many authors [39,40], explains the occurrence of thrombocytopenia in preeclampsia, which primarily appears as consumption thrombocytopenia and may precede the overt clinical and laboratory manifestation of preeclampsia.

Conclusions

1. The comparative analysis revealed no differences in the levels of NETs in healthy pregnant women and patients with gestational thrombocytopenia which could indicate the physiological nature of the latter.

2. A significant increase in the levels of NETs in preeclampsia requires further study of the feasibility of using NETs assessment for early diagnosis of this complication in high-risk patients.

3. Significant differences in the level of NETs between patients with pre-eclampsia and those with gestational thrombocytopenia suggest using the studied method for the differential diagnosis of these conditions.

Disclosure. The authors declare that they have no competing interests.

Authors’ ORCID

Kuzina N.B. - 0000-0002-1223-8740
Plakhotina E.N. - 0000-0002-6793-2318
Kuzovlev A.N. - 0000-0002-5930-0118
Belousova T.N. - 0000-0003-3804-7691
Bryantsev E.V. - 0000-0001-6155-9404
Kasina D.V. - 0000-0002-6759-9121

Литература/References

Differential diagnostic capabilities of calculating the level of neutrophil extracellular traps


Differential diagnostic capabilities of calculating the level of neutrophil extracellular traps